{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Larotaxel",
  "nciThesaurus": {
    "casRegistry": "156294-36-9",
    "chebiId": "",
    "chemicalFormula": "C45H53NO14",
    "definition": "A semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic activities. Larotaxel binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. Larotaxel penetrates the blood brain barrier.",
    "fdaUniiCode": "TWQ8K8A81Y",
    "identifier": "C48427",
    "preferredName": "Larotaxel",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C1490",
      "C67437"
    ],
    "synonyms": [
      "LAROTAXEL",
      "Larotaxel",
      "RPR 109881A",
      "RPR-109881",
      "Taxoid-109881",
      "XRP9881"
    ]
  }
}